Phathom Pharmaceuticals Inc. has announced a significant update from the U.S. Food and Drug Administration (FDA) regarding its gastrointestinal treatment, VOQUEZNA® (vonoprazan) tablets. The FDA has corrected its Orange Book listing to accurately reflect a full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA, effective through May 3, 2032. This update affirms the long-term commercial potential of the product as a first-in-class treatment. The exclusivity ensures that VOQUEZNA remains protected from generic competition in the U.S., solidifying its market position. No other organizations are involved in this regulatory exclusivity update.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.